GDR Stock Overview
A molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
genedrive plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.015 |
52 Week High | UK£0.21 |
52 Week Low | UK£0.015 |
Beta | 0.036 |
1 Month Change | -66.29% |
3 Month Change | -71.90% |
1 Year Change | -92.80% |
3 Year Change | -97.78% |
5 Year Change | -92.98% |
Change since IPO | -99.17% |
Recent News & Updates
Recent updates
Is genedrive (LON:GDR) In A Good Position To Invest In Growth?
Mar 08Here's Why We're Watching genedrive's (LON:GDR) Cash Burn Situation
Jul 11We're A Little Worried About genedrive's (LON:GDR) Cash Burn Rate
Aug 30Here's Why genedrive (LON:GDR) Must Use Its Cash Wisely
May 17Is genedrive's (LON:GDR) Share Price Gain Of 252% Well Earned?
Jan 29Shareholder Returns
GDR | GB Life Sciences | GB Market | |
---|---|---|---|
7D | -20.3% | -1.1% | -0.6% |
1Y | -92.8% | -45.7% | 6.3% |
Return vs Industry: GDR underperformed the UK Life Sciences industry which returned -45.7% over the past year.
Return vs Market: GDR underperformed the UK Market which returned 6.3% over the past year.
Price Volatility
GDR volatility | |
---|---|
GDR Average Weekly Movement | 27.2% |
Life Sciences Industry Average Movement | 7.1% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.2% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: GDR's share price has been volatile over the past 3 months.
Volatility Over Time: GDR's weekly volatility has increased from 18% to 27% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 43 | James Cheek | www.genedriveplc.com |
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive system, a rapid thermocycler and signal detection system and semi- automated system used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests.
genedrive plc Fundamentals Summary
GDR fundamental statistics | |
---|---|
Market cap | UK£8.01m |
Earnings (TTM) | -UK£5.00m |
Revenue (TTM) | UK£272.00k |
29.5x
P/S Ratio-1.6x
P/E RatioIs GDR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GDR income statement (TTM) | |
---|---|
Revenue | UK£272.00k |
Cost of Revenue | UK£3.81m |
Gross Profit | -UK£3.54m |
Other Expenses | UK£1.46m |
Earnings | -UK£5.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0092 |
Gross Margin | -1,301.47% |
Net Profit Margin | -1,837.50% |
Debt/Equity Ratio | 0% |
How did GDR perform over the long term?
See historical performance and comparison